Search - tctmd.com

Displaying 1 - 20 of 46

Sort: Relevancy | Date

Presentation TCT 2025

TCT 1093: A Novel Cell-permeable Peptide Therapeutic for Reperfusion Injury Following Myocardial Infarction

Presenter: Lucas Shores

October 28, 2025

News Conference News TCT 2024

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

Caitlin E. Cox

October 28, 2024

Presentation TCT 2019

Newest Stem Cell Therapies are Effective in Treating Lower Extremity Ischemia

Presenter: Marianne Brodmann

September 25, 2019

Presentation TCT 2017

CAREMI: A Randomized Double-Blind Trial Evaluating Allogeneic Cardiac Stem Cells In Acute Myocardial Infarction

Presenter: Daniel Burkhoff, JoAnn Lindenfeld, Francisco Fdez-Aviles

October 31, 2017

Presentation TCT 2017

New Products: Ixmyelocel and Allogeneic Mesenchymal Stem Cells

Presenter: Francisco Fdez-Aviles, Emerson C. Perin, Timothy D. Henry

October 31, 2017

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

Presentation TCT 2015

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Philippe Menasché

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Amit Patel

October 15, 2015

$Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!$

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Emerson C. Perin

October 15, 2015

Presentation TCT 2015

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Ricardo Sanz-Ruiz

October 15, 2015

Presentation TCT 2015

Stem CellBased Ablation for Ventricular Arrhythmias

Presenter: Nabil Dib, Philippe Menasché, Angel Arenal

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

Presenter: Nabil Dib, Philippe Menasché, Marc S. Penn

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

Presenter: Nabil Dib, Philippe Menasché, Timothy D. Henry

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Jay H Traverse

October 15, 2015

Presentation TCT 2015

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

Presenter: Nabil Dib, Philippe Menasché, Amit Patel

October 15, 2015

Presentation TCT 2015

Stem Cells in Biology of the Adult Myocardium: Are Biomaterials the Missing Link?

Presenter: Francisco Fdez-Aviles, Timothy D. Henry, Jay H Traverse

October 15, 2015

News Conference News TCT 2015

Despite Setbacks, Research Into Myocardial Salvage Continues

October 12, 2015

Presentation TCT 2014

ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration (ALLSTAR): The Six-Month Phase I Safety Results

Presenter: Daniel Burkhoff, William W. O'Neill, Jose Luis Assad-Morell, Raj Makkar

September 16, 2014

Presentation TCT 2014

Impact of Intracoronary Injection of CD133+ Bone Marrow Stem Cells on Coronary Atherosclerotic Progression in Patients with STEMI: A COMPARE-AMI IVUS Substudy

Presenter: Fuyu Qiu

September 16, 2014

Advertisement

TCT 1093: A Novel Cell-permeable Peptide Therapeutic for Reperfusion Injury Following Myocardial Infarction

DCB Outdo Noncompliant Balloons in Simple Bifurcation Side Branches: DCB-BIF

Newest Stem Cell Therapies are Effective in Treating Lower Extremity Ischemia

CAREMI: A Randomized Double-Blind Trial Evaluating Allogeneic Cardiac Stem Cells In Acute Myocardial Infarction

New Products: Ixmyelocel and Allogeneic Mesenchymal Stem Cells

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

First-in-Man Experience With Human Embryonic Stem Cell-Derived Progenitors for Heart Failure

Debate: Are We Really Ready for Phase III Trials? For Limb Ischemia There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? For Refractory Angina There Are Knowns and Unknowns!

Debate: Are We Really Ready for Phase III Trials? Yes, Mesenchymal Cells Are Ready to Be Tested for Prevention and Treatment of Chronic Ischemic and Nonischemic Heart Failure!

Debate: Are We Really Ready for Phase III Trials? Yes, in STEMI Bone Marrow Mononuclear Fraction Is Ready, and Other Options Are Coming!

Stem CellBased Ablation for Ventricular Arrhythmias

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? No Cell Works. Genes are the Answer.

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiac Progenitor Cells Are the Only One!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Combination of Cells for Additive Effects: This Is the Key!

In Patients With End-stage Coronary Artery Disease With Ischemia and Scar, Which Cell Type Will Work Best? Cardiopoietic Commitment Is the Key!

Stem Cells in Biology of the Adult Myocardium: Are Biomaterials the Missing Link?

Despite Setbacks, Research Into Myocardial Salvage Continues

ALLogeneic Heart STem Cells To Achieve Myocardial Regeneration (ALLSTAR): The Six-Month Phase I Safety Results

Impact of Intracoronary Injection of CD133+ Bone Marrow Stem Cells on Coronary Atherosclerotic Progression in Patients with STEMI: A COMPARE-AMI IVUS Substudy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content